



Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)

Descrizione

COMUNICATO STAMPA - CONTENUTO PROMOZIONALE

Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications

SEOUL, South Korea, June 1, 2026 /PRNewswire/ - Hanmi Pharm. Co., Ltd. (Hanmi) today announced that they have entered into a license agreement for the development, manufacturing and commercialization of Hanmi's biologic drug candidate sonefpeglutide (LAPSGLP-2 analog) with Eli Lilly and Company (Lilly).

Sonefpeglutide is a novel drug candidate incorporating Hanmi's proprietary long-acting platform technology, LAPSCOVERY. Hanmi has previously received FDA marketing approval for a biologic incorporating its LAPSCOVERY platform and is currently conducting additional global clinical trials for five other programs utilizing the same platform.

Hanmi has focused on the biological functions of glucagon-like peptide 2 (GLP-2) including the promotion of intestinal growth, reduction of inflammation, and protection and regeneration of the intestinal mucosa and has demonstrated these effects through a range of non-clinical studies. The company has also presented the therapeutic potential of LAPSGLP-2 across multiple indications at major scientific conferences. Hanmi is currently conducting a global Phase 2 clinical trial in short bowel syndrome (SBS).

Hanmi will continue to conduct the ongoing global Phase 2 trial in SBS through completion while Lilly will explore additional clinical trials for sonefpeglutide based on its nonclinical and clinical data.

Through this agreement, Lilly will obtain exclusive rights to develop, manufacture and commercialize sonefpeglutide worldwide, excluding Korea.

Juhyun Lim, Vice Chairman of Hanmi, stated, "It is highly meaningful that Lilly, one of the most closely watched innovators globally, has highly recognized the development potential for sonefpeglutide." She added, "Hanmi will continue to advance innovative drug development, guided by our mission of 'Respect for People and Value Creation.'"

Under the agreement, Hanmi will receive an upfront payment of USD 75 million and may receive up to an additional USD 1.185 billion in clinical development, regulatory approval and commercialization milestone payments. In addition, Hanmi will be eligible to receive royalties following product launch.

About Hanmi Pharm. Co., Ltd.

Hanmi is an R&D-focused pharmaceutical company committed to developing globally innovative therapies in areas of high unmet medical needs such as obesity/metabolism, oncology, and rare diseases. Hanmi leverages proprietary platform technologies, including long-acting biologics and bispecific antibodies, to address unmet medical needs. The company emphasizes open innovation and has established numerous global partnerships to advance its research and development efforts. For more information, please visit www.hanmipharm.com.

â? Contact info: Hanmi Pharm. Co., Ltd. (www.hanmipharm.com,
www.linkedin.com/company/hanmipharm) innovation@hanmi.co.kr, +82-02-410-0467

Logo â?? https://mma.prnewswire.com/media/2034330/Hanmi_Pharmaceutical_Logo.jpg

View original content: <https://www.prnewswire.co.uk/news-releases/hanmi-signs-licensing-deal-with-lilly-for-sonefpegglutide-lapsglp-2-analog-302786590.html>

Copyright 2026 PR Newswire. All Rights Reserved.

COMUNICATO STAMPA â?? CONTENUTO PROMOZIONALE: Immediapress Ã un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dallâ??ente che lo emette. Lâ??Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

â??

immediapress/pr-newswire

Categoria

1. Comunicati

Tag

1. ImmediaPress

Data di creazione

Giugno 1, 2026

Autore

redazione